FindTrial
Sign In

Remsima 100 mg powder for concentrate for solution for infusion

DRUG8 trials

Sponsors

AstraZeneca AB, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif, Centre Medico Chirurgical Ambroise Pare Hartmann, St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr

Conditions

Axial SpondyloarthritisCrohn's DiseaseCrohn's diseaseCrohn´s diseaseImmune Bowel Disease (including Crohn's disease and Ulcerative colitis).Locally advanced cervical cancerMetastatic Non-Small Cell Lung Cancer (mNSCLC)NSQ NSCLC

Phase 2

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Participants with Solid Tumors (eVOLVE 01). Substudy 1: Volrustomig + Chemotherapy as 1L Treatment in Participants with Advanced or Metastatic NSCLC NSQ and PD-L1 TPS xx Substudy 2: Volrustomig + Ramucirumab + Chemotherapy as 1L Treatment in Participants with Advanced or Metastatic NSCLC SQ or NSQ and PD-L1 TPS xx
RecruitingCTIS2023-509482-20-00
AstraZeneca ABNSQ NSCLC, Solid Tumors, SQ
Start: 2024-12-03Target: 91Updated: 2025-10-21

Phase 3

A Phase III, Two- Arm, Parallel, Randomized, Multi-Center, Open‑Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)
SuspendedCTIS2023-503298-39-00
AstraZeneca ABMetastatic Non-Small Cell Lung Cancer (mNSCLC)
Start: 2024-06-13Target: 437Updated: 2025-12-15
A Phase III, Randomized, Double blind, Placebo controlled, Multi centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum based, Concurrent Chemoradiation Therapy (eVOLVE Cervical)
RecruitingCTIS2023-504374-38-00
AstraZeneca ABLocally advanced cervical cancer
Start: 2024-04-12Target: 101Updated: 2025-09-25
Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients with Active Crohn’s Disease or Ulcerative Colitis
CompletedCTIS2023-508584-72-00
Centre Medico Chirurgical Ambroise Pare HartmannImmune Bowel Disease (including Crohn's disease and Ulcerative colitis).
Start: 2024-07-10End: 2025-05-14Target: 130Updated: 2024-07-30

Phase 4

Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL trial
Active, not recruitingCTIS2023-508242-18-00
Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube DigestifCrohn's disease
Start: 2021-12-21Target: 185Updated: 2025-09-17
Prospective Analysis of Pharmacokinetic Infliximab data in Paediatric Inflammatory Bowel Disease patients (Pro-RAPID)
Not yet recruitingCTIS2023-507352-72-00
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Crohn's Disease
Target: 50Updated: 2026-01-08
Stopping anti-TNF treatment in Crohn's and Colitis patients in remission
RecruitingCTIS2024-513299-17-00
Region SkaneCrohn´s disease, Ulcerative colitis
Start: 2017-05-05Target: 350Updated: 2024-09-09
Direct comparison between NSAIDs and biosimilar TNFa blockers in patients with axial spondyloarthritis
RecruitingCTIS2024-513213-13-00
St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-RuhrAxial Spondyloarthritis
Start: 2025-03-13Target: 100Updated: 2025-09-06